Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $132000.0.

  • Guided Therapeutics' Treasury Shares changed 0.0% to $132000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $132000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $132000.0 for FY2024, which is 0.0% changed from last year.
  • As of Q3 2024, Guided Therapeutics' Treasury Shares stood at $678000.0, which was down 0.0% from $678000.0 recorded in Q2 2024.
  • In the past 5 years, Guided Therapeutics' Treasury Shares ranged from a high of $678000.0 in Q2 2021 and a low of $678000.0 during Q2 2021
  • Moreover, its 4-year median value for Treasury Shares was $678000.0 (2021), whereas its average is $678000.0.
  • The largest annual percentage gain for Guided Therapeutics' Treasury Shares in the last 5 years was 0.0% (2021), contrasted with its biggest fall of 0.0% (2021).
  • Guided Therapeutics' Treasury Shares (Quarter) stood at $132000.0 in 2021, then changed by 0.0% to $132000.0 in 2022, then changed by 0.0% to $132000.0 in 2023, then changed by 0.0% to $132000.0 in 2024, then changed by 0.0% to $132000.0 in 2025.
  • Its Treasury Shares was $132000.0 in Q3 2025, compared to $132000.0 in Q2 2025 and $132000.0 in Q1 2025.